{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:28:34Z","timestamp":1777879714607,"version":"3.51.4"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/ja.2017.115","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T06:21:19Z","timestamp":1507702879000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Current landscape and future prospects of antiviral drugs derived from microbial products"],"prefix":"10.1038","volume":"71","author":[{"given":"Naoki","family":"Takizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"BFja2017115_CR1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695\u2013747 (2016).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFja2017115_CR2","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1021\/cr4006318","volume":"115","author":"V Gogineni","year":"2015","unstructured":"Gogineni, V., Schinazi, R. F. & Hamann, M. T. Role of marine natural products in the genesis of antiviral agents. Chem. Rev. 115, 9655\u20139706 (2015).","journal-title":"Chem. Rev."},{"key":"BFja2017115_CR3","first-page":"96","volume":"17","author":"M Hori","year":"1964","unstructured":"Hori, M., Takita, T., Koyama, G., Takeuchi, T. & Umezawa, H. A new antibiotic, Formycin. J. Antibiot. (Tokyo) 17, 96\u201399 (1964).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR4","first-page":"286","volume":"19","author":"T Takeuchi","year":"1966","unstructured":"Takeuchi, T., Iwanaga, J., Aoyagi, T. & Umezawa, H. Antiviral effect of formycin and formycin B. J. Antibiot. (Tokyo) 19, 286\u2013287 (1966).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR5","first-page":"227","volume":"20","author":"T Sawa","year":"1967","unstructured":"Sawa, T., Fukagawa, Y., Homma, I., Takeuchi, T. & Umezawa, H. Mode of inhibition of coformycin on adenosine deaminase. J. Antibiot. (Tokyo) 20, 227\u2013231 (1967).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.7164\/antibiotics.34.1216","volume":"34","author":"N Shimada","year":"1981","unstructured":"Shimada, N. et al. Oxanosine, a novel nucleoside from actinomycetes. J. Antibiot. (Tokyo) 34, 1216\u20131218 (1981).","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"1","key":"BFja2017115_CR7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/nass\/42.1.19","volume":"42","author":"Y. Saito","year":"1999","unstructured":"Saito, Y. et al. Synthesis and anti-HIV activity of unusual nucleoside oxanosine derivatives. Nucleic Acids Symp. Ser. 19\u201320 (1999) at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10780358.","journal-title":"Nucleic Acids Symposium Series"},{"key":"BFja2017115_CR8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.7164\/antibiotics.34.1219","volume":"34","author":"H Nakamura","year":"1981","unstructured":"Nakamura, H. et al. The X-ray structure determination of oxanosine. J. Antibiot. (Tokyo) 34, 1219\u20131221 (1981).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7164\/antibiotics.42.344","volume":"42","author":"H Hoshino","year":"1989","unstructured":"Hoshino, H., Seki, J. & Takeuchi, T. New antifungal antibiotics, benanomicins A and B inhibit infection of T-cell with human immunodeficiency virus (HIV) and syncytium formation by HIV. J. Antibiot. (Tokyo) 42, 344\u2013346 (1989).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7164\/antibiotics.44.569","volume":"44","author":"M Nakamura","year":"1991","unstructured":"Nakamura, M., Ohno, T., Kunimoto, S., Naganawa, H. & Takeuchi, T. Kijimicin: an inhibitor of human immunodeficiency virus in acutely and chronically infected cells. J. Antibiot. (Tokyo) 44, 569\u2013571 (1991).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7164\/antibiotics.49.113","volume":"49","author":"S Kondo","year":"1996","unstructured":"Kondo, S. et al. New bellenamine homologs inhibiting human immunodeficiency virus type I infectivity. J. Antibiot. (Tokyo) 49, 113\u2013118 (1996).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7164\/antibiotics.42.611","volume":"42","author":"K Ajito","year":"1989","unstructured":"Ajito, K. et al. Inhibition of human immunodeficiency virus-associated reverse transcriptase by 14-O-acyladriamycins. J. Antibiot. (Tokyo) 42, 611\u2013619 (1989).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR13","first-page":"719","volume":"14","author":"S Atsumi","year":"1988","unstructured":"Atsumi, S. et al. Inhibition of human immunodeficiency virus-associated reverse transcriptase by aminoacridines. Drugs Exp. Clin. Res. 14, 719\u2013722 (1988).","journal-title":"Drugs Exp. Clin. Res."},{"key":"BFja2017115_CR14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/jvi.8.1.28-34.1971","volume":"8","author":"G Koch","year":"1971","unstructured":"Koch, G. Differential effect of phleomycin on the infectivity of poliovirus and poliovirus-induced ribonucleic acids. J. Virol. 8, 28\u201334 (1971).","journal-title":"J. Virol."},{"key":"BFja2017115_CR15","first-page":"105","volume":"8","author":"JA Fernandez-Pol","year":"2011","unstructured":"Fernandez-Pol, J. A. Conservation of multifunctional ribosomal protein metallopanstimulin-1 (RPS27) through complex evolution demonstrates its key role in growth regulation in Archaea, eukaryotic cells, DNA repair, translation and viral replication. Cancer Genomics Proteomics 8, 105\u2013126 (2011).","journal-title":"Cancer Genomics Proteomics"},{"key":"BFja2017115_CR16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.7164\/antibiotics.36.1242","volume":"36","author":"A Tanaka","year":"1983","unstructured":"Tanaka, A., Sen, K., Morita, J. & Komano, T. Phage inactivation by aclacinomycin A and its analogues. J. Antibiot. (Tokyo) 36, 1242\u20131244 (1983).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7164\/antibiotics.33.83","volume":"33","author":"LA Dolak","year":"1980","unstructured":"Dolak, L. A. & DeBoer, C. Clazamycin B is antibiotic 354. J. Antibiot. (Tokyo) 33, 83\u201384 (1980).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.7164\/antibiotics.27.801","volume":"27","author":"M Koenuma","year":"1974","unstructured":"Koenuma, M., Kinashi, H. & Otake, N. An improved screening method for antiphage antibiotics and isolation of sarkomycin and its relatives. J. Antibiot. (Tokyo) 27, 801\u2013804 (1974).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR19","first-page":"277","volume":"20","author":"T Kunimoto","year":"1967","unstructured":"Kunimoto, T., Hori, M. & Umezawa, H. Modes of action of phleomycin, bleomycin and formycin on HeLa S3 cells in synchronized culture. J. Antibiot. (Tokyo) 20, 277\u2013281 (1967).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.7164\/antibiotics.22.283","volume":"22","author":"T Aoyagi","year":"1969","unstructured":"Aoyagi, T., Takeuchi, T., Matsuzaki, A., Kawamura, K. & Kondo, S. Leupeptins, new protease inhibitors from Actinomycetes. J. Antibiot. (Tokyo) 22, 283\u2013286 (1969).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.virol.2011.11.031","volume":"424","author":"K Gnir\u00df","year":"2012","unstructured":"Gnir\u00df, K. et al. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression. Virology 424, 3\u201310 (2012).","journal-title":"Virology"},{"key":"BFja2017115_CR22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7164\/antibiotics.25.263","volume":"25","author":"H Suda","year":"1972","unstructured":"Suda, H., Aoyagi, T., Hamada, M., Takeuchi, T. & Umezawa, H. Antipain, a new protease inhibitor isolated from actinomycetes. J. Antibiot. (Tokyo) 25, 263\u2013266 (1972).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7164\/antibiotics.26.787","volume":"26","author":"H Umezawa","year":"1973","unstructured":"Umezawa, H., Aoyagi, T., Okura, A., Morishima, H. & Takeuchi, T. Elastatinal, a new elastase inhibitor produced by actinomycetes. J. Antibiot. (Tokyo) 26, 787\u2013789 (1973).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR24","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1128\/jvi.67.8.4688-4695.1993","volume":"67","author":"A Molla","year":"1993","unstructured":"Molla, A., Hellen, C. U. & Wimmer, E. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J. Virol. 67, 4688\u20134695 (1993).","journal-title":"J. Virol."},{"key":"BFja2017115_CR25","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1128\/JVI.78.18.10166-10177.2004","volume":"78","author":"GA Belov","year":"2004","unstructured":"Belov, G. A. et al. Bidirectional increase in permeability of nuclear envelope upon poliovirus infection and accompanying alterations of nuclear pores. J. Virol. 78, 10166\u201310177 (2004).","journal-title":"J. Virol."},{"key":"BFja2017115_CR26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7164\/antibiotics.23.259","volume":"23","author":"H Umezawa","year":"1970","unstructured":"Umezawa, H., Aoyagi, T., Morishima, H., Matsuzaki, M. & Hamada, M. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J. Antibiot. (Tokyo) 23, 259\u2013262 (1970).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-5793(89)81251-7","volume":"247","author":"AD Richards","year":"1989","unstructured":"Richards, A. D., Roberts, R., Dunn, B. M., Graves, M. C. & Kay, J. Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett. 247, 113\u2013117 (1989).","journal-title":"FEBS Lett."},{"key":"BFja2017115_CR28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"NA Roberts","year":"1990","unstructured":"Roberts, N. A. et al. Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358\u2013361 (1990).","journal-title":"Science"},{"key":"BFja2017115_CR29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7164\/antibiotics.27.963","volume":"27","author":"H Umezawa","year":"1974","unstructured":"Umezawa, H., Aoyagi, T., Komiyama, T., Morishima, H. & Hamada, M. Purification and characterization of a sialidase inhibitor, siastatin, produced by Streptomyces. J. Antibiot. (Tokyo) 27, 963\u2013969 (1974).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR30","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.7164\/antibiotics.46.1883","volume":"46","author":"Y Nishimura","year":"1993","unstructured":"Nishimura, Y. et al. Synthesis of 3-episiastatin B analogues having anti-influenza virus activity. J. Antibiot. (Tokyo) 46, 1883\u20131889 (1993).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR31","unstructured":"World Health OrganizationMedia centre. Influenza (Seasonal) Fact sheet. http:\/\/www.who.int\/mediacentre\/factsheets\/fs211\/en\/."},{"issue":"1","key":"BFja2017115_CR32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev-virology-101416-041726","volume":"4","author":"Anice C. Lowen","year":"2017","unstructured":"Lowen, A. C. Constraints, drivers, and implications of influenza a virus reassortment. Annu. Rev. Virol.(e-pub ahead of print; doi: 10.1146\/annurev-virology-101416-041726) (2017)","journal-title":"Annual Review of Virology"},{"key":"BFja2017115_CR33","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.144.3620.862","volume":"144","author":"WL Davies","year":"1964","unstructured":"Davies, W. L. et al. Antiviral activity of 1-adamantanamine (amantadine). Science 144, 862\u2013863 (1964).","journal-title":"Science"},{"key":"BFja2017115_CR34","doi-asserted-by":"crossref","first-page":"9396","DOI":"10.1073\/pnas.1401997111","volume":"111","author":"R Liang","year":"2014","unstructured":"Liang, R., Li, H., Swanson, J. M. J. & Voth, G. A. Multiscale simulation reveals a multifaceted mechanism of proton permeation through the influenza A M2 proton channel. Proc. Natl Acad. Sci. USA 111, 9396\u20139401 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFja2017115_CR35","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature06528","volume":"451","author":"M Hong","year":"2008","unstructured":"Hong, M. & Degrado, W. F. Structural basis for proton conduction and inhibition by the influenza M2 protein. Nature 451, 596\u2013599 (2008).","journal-title":"Nature"},{"key":"BFja2017115_CR36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0042-6822(74)90080-4","volume":"58","author":"P Meindl","year":"1974","unstructured":"Meindl, P., Bodo, G., Palese, P., Schulman, J. & Tuppy, H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 58, 457\u2013463 (1974).","journal-title":"Virology"},{"key":"BFja2017115_CR37","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1021\/bi00193a002","volume":"33","author":"MN Janakiraman","year":"1994","unstructured":"Janakiraman, M. N., White, C. L., Laver, W. G., Air, G. M. & Luo, M. Structure of influenza virus neuraminidase B\/Lee\/40 complexed with sialic acid and a dehydro analog at 1.8-A resolution: implications for the catalytic mechanism. Biochemistry 33, 8172\u20138179 (1994).","journal-title":"Biochemistry"},{"key":"BFja2017115_CR38","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/jm00031a011","volume":"37","author":"NR Taylor","year":"1994","unstructured":"Taylor, N. R. & von Itzstein, M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J. Med. Chem. 37, 616\u2013624 (1994).","journal-title":"J. Med. Chem."},{"key":"BFja2017115_CR39","first-page":"165","volume":"24","author":"AK Chong","year":"1991","unstructured":"Chong, A. K., Pegg, M. S. & von Itzstein, M. Characterisation of an ionisable group involved in binding and catalysis by sialidase from influenza virus. Biochem. Int. 24, 165\u2013171 (1991).","journal-title":"Biochem. Int."},{"key":"BFja2017115_CR40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","volume":"363","author":"M von Itzstein","year":"1993","unstructured":"von Itzstein, M. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418\u2013423 (1993).","journal-title":"Nature"},{"key":"BFja2017115_CR41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/ja963036t","volume":"119","author":"CU Kim","year":"1997","unstructured":"Kim, C. U. et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119, 681\u2013690 (1997).","journal-title":"J. Am. Chem. Soc."},{"key":"BFja2017115_CR42","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1128\/AAC.41.9.1949","volume":"41","author":"EJ Eisenberg","year":"1997","unstructured":"Eisenberg, E. J., Bidgood, A. & Cundy, K. C. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob. Agents Chemother. 41, 1949\u20131952 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/AAC.45.3.743-748.2001","volume":"45","author":"DF Smee","year":"2001","unstructured":"Smee, D. F., Huffman, J. H., Morrison, A. C., Barnard, D. L. & Sidwell, R. W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45, 743\u2013748 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.00333-08","volume":"53","author":"M Yamashita","year":"2009","unstructured":"Yamashita, M. et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 53, 186\u2013192 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","volume":"14","author":"AJW te Velthuis","year":"2016","unstructured":"te Velthuis, A. J. W. & Fodor, E. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat. Rev. Microbiol. 14, 479\u2013493 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFja2017115_CR46","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","volume":"59","author":"RA Byrn","year":"2015","unstructured":"Byrn, R. A. et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob. Agents Chemother. 59, 1569\u20131582 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR47","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","volume":"57","author":"MP Clark","year":"2014","unstructured":"Clark, M. P. et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J. Med. Chem. 57, 6668\u20136678 (2014).","journal-title":"J. Med. Chem."},{"key":"BFja2017115_CR48","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","volume":"177","author":"RW Sidwell","year":"1972","unstructured":"Sidwell, R. W. et al. Broad-spectrum antiviral activity of virazole: 1-f8- D-ribofuranosyl- 1,2,4-triazole- 3-carboxamide. Science 177, 705\u2013706 (1972).","journal-title":"Science"},{"key":"BFja2017115_CR49","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/AAC.11.6.946","volume":"11","author":"B Eriksson","year":"1977","unstructured":"Eriksson, B. et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11, 946\u2013951 (1977).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR50","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","volume":"46","author":"Y Furuta","year":"2002","unstructured":"Furuta, Y. et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46, 977\u2013981 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","volume":"49","author":"Y Furuta","year":"2005","unstructured":"Furuta, Y. et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49, 981\u2013986 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR52","doi-asserted-by":"crossref","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","volume":"8","author":"Z Jin","year":"2013","unstructured":"Jin, Z., Smith, L. K., Rajwanshi, V. K., Kim, B. & Deval, J. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2019-triphosphate towards influenza A virus polymerase. PLoS ONE 8, e68347 (2013).","journal-title":"PLoS ONE"},{"key":"BFja2017115_CR53","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","volume":"87","author":"T Baranovich","year":"2013","unstructured":"Baranovich, T. et al. T-705 (Favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 87, 3741\u20133751 (2013).","journal-title":"J. Virol."},{"key":"BFja2017115_CR54","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","volume":"57","author":"H Sangawa","year":"2013","unstructured":"Sangawa, H. et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob. Agents Chemother. 57, 5202\u20135208 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1039\/C1NP00053E","volume":"29","author":"U Grienke","year":"2012","unstructured":"Grienke, U. et al. Influenza neuraminidase: a druggable target for natural products. Nat. Prod. Rep. 29, 11\u201336 (2012).","journal-title":"Nat. Prod. Rep."},{"key":"BFja2017115_CR56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7164\/antibiotics.55.165","volume":"55","author":"K Minagawa","year":"2002","unstructured":"Minagawa, K., Kouzuki, S. & Kamigauchi, T. Stachyflin and acetylstachyflin, novel anti-influenza A virus substances, produced by Stachybotrys sp. RF-7260. II. Synthesis and preliminary structure-activity relationships of stachyflin derivatives. J. Antibiot. (Tokyo) 55, 165\u2013171 (2002).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7164\/antibiotics.55.155","volume":"55","author":"K Minagawa","year":"2002","unstructured":"Minagawa, K. et al. Stachyflin and acetylstachyflin, novel anti-influenza A virus substances, produced by Stachybotrys sp. RF-7260. I. Isolation, structure elucidation and biological activities. J. Antibiot. (Tokyo) 55, 155\u2013164 (2002).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR58","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1021\/ol0271032","volume":"4","author":"M Nakatani","year":"2002","unstructured":"Nakatani, M., Nakamura, M., Suzuki, A., Inoue, M. & Katoh, T. A new strategy toward the total synthesis of stachyflin, a potent anti-influenza a virus agent: concise route to the tetracyclic core structure. Org. Lett. 4, 4483\u20134486 (2002).","journal-title":"Org. Lett."},{"key":"BFja2017115_CR59","unstructured":"World Health Organization Global Health Sector Strategy on Viral Hepatitis 2016-2021, World Health Organization, Geneva, Switzerland, (2016)."},{"key":"BFja2017115_CR60","unstructured":"World Health OrganizationMedia centre. Fact sheets. Hepatitis B (2017) http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/Accessed 27 May 2017."},{"key":"BFja2017115_CR61","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2014.01.046","volume":"75","author":"F Zhang","year":"2014","unstructured":"Zhang, F. & Wang, G. A review of non-nucleoside anti-hepatitis B virus agents. Eur. J. Med. Chem. 75, 267\u2013281 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"BFja2017115_CR62","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3748\/wjg.v22.i1.188","volume":"22","author":"Y-H Wu","year":"2016","unstructured":"Wu, Y.-H. Naturally derived anti-hepatitis B virus agents and their mechanism of action. World J. Gastroenterol. 22, 188\u2013204 (2016).","journal-title":"World J. Gastroenterol."},{"key":"BFja2017115_CR63","first-page":"1","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1, 1\u201328 (2012).","journal-title":"Elife"},{"key":"BFja2017115_CR64","unstructured":"Hepatitis B Foundation. Treatment & Management. Drug Watch (2017) http:\/\/www.hepb.org\/treatment-and-management\/drug-watch\/Accessed 27 May 2017."},{"key":"BFja2017115_CR65","doi-asserted-by":"crossref","first-page":"12558","DOI":"10.3748\/wjg.v21.i44.12558","volume":"21","author":"S Manzoor","year":"2015","unstructured":"Manzoor, S. Hepatitis B virus therapy: what\u2019s the future holding for us? World J. Gastroenterol. 21, 12558 (2015).","journal-title":"World J. Gastroenterol."},{"key":"BFja2017115_CR66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.38.4.707","volume":"38","author":"T Nagahata","year":"1994","unstructured":"Nagahata, T., Kitagawa, M. & Matsubara, K. Effect of oxetanocin G, a novel nucleoside analog, on DNA synthesis by hepatitis B virus virions. Antimicrob. Agents Chemother. 38, 707\u2013712 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR67","doi-asserted-by":"crossref","first-page":"644","DOI":"10.7164\/antibiotics.42.644","volume":"42","author":"T Nagahata","year":"1989","unstructured":"Nagahata, T., Ueda, K., Tsurimoto, T., Chisaka, O. & Matsubara, K. Anti-hepatitis B virus activities of purine derivatives of oxetanocin A. J. Antibiot. (Tokyo) 42, 644\u2013646 (1989).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR68","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.3748\/wjg.v20.i24.7707","volume":"20","author":"X Wang","year":"2014","unstructured":"Wang, X. Emerging antivirals for the treatment of hepatitis B. World J. Gastroenterol. 20, 7707 (2014).","journal-title":"World J. Gastroenterol."},{"key":"BFja2017115_CR69","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/jvi.64.6.2819-2824.1990","volume":"64","author":"J Summers","year":"1990","unstructured":"Summers, J., Smith, P. M. & Horwich, A. L. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64, 2819\u20132824 (1990).","journal-title":"J. Virol."},{"key":"BFja2017115_CR70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","volume":"51","author":"M Levrero","year":"2009","unstructured":"Levrero, M. et al. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51, 581\u2013592 (2009).","journal-title":"J. Hepatol."},{"key":"BFja2017115_CR71","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/aps.2013.175","volume":"35","author":"L Yang","year":"2014","unstructured":"Yang, L. et al. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol. Sin. 35, 410\u2013418 (2014).","journal-title":"Acta Pharmacol. Sin."},{"key":"BFja2017115_CR72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2015.11.004","volume":"125","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation. Antiviral Res. 125, 25\u201333 (2016).","journal-title":"Antiviral Res."},{"key":"BFja2017115_CR73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","volume":"99","author":"Y Hu","year":"2013","unstructured":"Hu, Y., Cheng, X., Cao, F., Huang, A. & Tavis, J. E. \u03b2-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res. 99, 221\u2013229 (2013).","journal-title":"Antiviral Res."},{"key":"BFja2017115_CR74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1128\/AAC.04617-14","volume":"59","author":"G Lu","year":"2015","unstructured":"Lu, G. et al. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrob. Agents Chemother. 59, 1070\u20131079 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7164\/antibiotics.39.589","volume":"39","author":"S Kitamura","year":"1986","unstructured":"Kitamura, S., Iida, T., Shirahata, K. & Kase, H. Studies on lipoxygenase inhibitors. I. MY3-469 (3-methoxytropolone), a potent and selective inhibitor of 12-lipoxygenase, produced by Streptoverticillium hadanonense KY11449. J. Antibiot. (Tokyo) 39, 589\u2013593 (1986).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR76","doi-asserted-by":"crossref","first-page":"41851","DOI":"10.1038\/srep41851","volume":"7","author":"M Suzuki","year":"2017","unstructured":"Suzuki, M. et al. Efficient genome replication of hepatitis B virus using adenovirus vector: a compact pregenomic RNA-expression unit. Sci. Rep. 7, 41851 (2017).","journal-title":"Sci. Rep."},{"key":"BFja2017115_CR77","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000360938","volume":"57","author":"A Gehring","year":"2014","unstructured":"Gehring, A., Bertoletti, A. & Tavis, J. E. Host factor-targeted hepatitis B virus therapies. Intervirology 57, 158\u2013162 (2014).","journal-title":"Intervirology"},{"key":"BFja2017115_CR78","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/jmv.23916","volume":"86","author":"S Ezzikouri","year":"2014","unstructured":"Ezzikouri, S. et al. Recent insights into hepatitis B virus-host interactions. J. Med. Virol. 86, 925\u2013932 (2014).","journal-title":"J. Med. Virol."},{"key":"BFja2017115_CR79","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","volume":"79","author":"P Gripon","year":"2005","unstructured":"Gripon, P., Cannie, I. & Urban, S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79, 1613\u20131622 (2005).","journal-title":"J. Virol."},{"key":"BFja2017115_CR80","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","volume":"58","author":"T Volz","year":"2013","unstructured":"Volz, T. et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J. Hepatol. 58, 861\u2013867 (2013).","journal-title":"J. Hepatol."},{"key":"BFja2017115_CR81","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","volume":"60","author":"S Nkongolo","year":"2014","unstructured":"Nkongolo, S. et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J. Hepatol. 60, 723\u2013731 (2014).","journal-title":"J. Hepatol."},{"key":"BFja2017115_CR82","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","volume":"59","author":"K Watashi","year":"2014","unstructured":"Watashi, K. et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59, 1726\u20131737 (2014).","journal-title":"Hepatology"},{"key":"BFja2017115_CR83","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1073\/pnas.91.6.2235","volume":"91","author":"TM Block","year":"1994","unstructured":"Block, T. M. et al. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 91, 2235\u20132239 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFja2017115_CR84","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nm0598-610","volume":"4","author":"TM Block","year":"1998","unstructured":"Block, T. M. et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med. 4, 610\u2013614 (1998).","journal-title":"Nat. Med."},{"key":"BFja2017115_CR85","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1042\/BST20160182","volume":"45","author":"DS Alonzi","year":"2017","unstructured":"Alonzi, D. S., Scott, K. A., Dwek, R. A. & Zitzmann, N. Iminosugar antivirals: the therapeutic sweet spot. Biochem. Soc. Trans. 45, 571\u2013582 (2017).","journal-title":"Biochem. Soc. Trans."},{"key":"BFja2017115_CR86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7164\/antibiotics.29.97","volume":"29","author":"H Umezawa","year":"1976","unstructured":"Umezawa, H., Aoyagi, T., Suda, H., Hamada, M. & Takeuchi, T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J. Antibiot. (Tokyo) 29, 97\u201399 (1976).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2249.1998.00466.x","volume":"111","author":"S Sasaki","year":"1998","unstructured":"Sasaki, S. et al. Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1. Clin. Exp. Immunol. 111, 30\u201335 (1998).","journal-title":"Clin. Exp. Immunol."},{"key":"BFja2017115_CR88","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00705-004-0417-5","volume":"150","author":"PJ Wright","year":"2005","unstructured":"Wright, P. J., Crameri, G. & Eaton, B. T. RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription. Arch. Virol. 150, 521\u2013532 (2005).","journal-title":"Arch. Virol."},{"key":"BFja2017115_CR89","doi-asserted-by":"crossref","first-page":"12111","DOI":"10.1128\/JVI.00560-07","volume":"81","author":"K-O Chang","year":"2007","unstructured":"Chang, K.-O. & George, D. W. Interferons and Ribavirin effectively inhibit norwalk virus replication in replicon-bearing cells. J. Virol. 81, 12111\u201312118 (2007).","journal-title":"J. Virol."},{"key":"BFja2017115_CR90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0166-3542(82)90027-4","volume":"2","author":"WC Koff","year":"1982","unstructured":"Koff, W. C., Elm, J. L. & Halstead, S. B. Antiviral effects if ribavirin and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitro. Antiviral Res. 2, 69\u201379 (1982).","journal-title":"Antiviral Res."},{"key":"BFja2017115_CR91","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1073\/pnas.70.4.1174","volume":"70","author":"DG Streeter","year":"1973","unstructured":"Streeter, D. G. et al. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl Acad. Sci. USA 70, 1174\u20131178 (1973).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFja2017115_CR92","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","volume":"105","author":"L Oestereich","year":"2014","unstructured":"Oestereich, L. et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 105, 17\u201321 (2014).","journal-title":"Antiviral Res."},{"key":"BFja2017115_CR93","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","volume":"104","author":"SJ Smither","year":"2014","unstructured":"Smither, S. J. et al. Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 104, 153\u2013155 (2014).","journal-title":"Antiviral Res"},{"key":"BFja2017115_CR94","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","volume":"508","author":"TK Warren","year":"2014","unstructured":"Warren, T. K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402\u2013405 (2014).","journal-title":"Nature"},{"key":"BFja2017115_CR95","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385 (2016).","journal-title":"Nature"},{"key":"BFja2017115_CR96","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2017.03.012","volume":"142","author":"L Eyer","year":"2017","unstructured":"Eyer, L. et al. Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. Antiviral Res. 142, 63\u201367 (2017).","journal-title":"Antiviral Res."},{"key":"BFja2017115_CR97","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","volume":"58","author":"JG Julander","year":"2014","unstructured":"Julander, J. G. et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. Antimicrob. Agents Chemother. 58, 6607\u20136614 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2017115_CR98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","volume":"137","author":"JG Julander","year":"2017","unstructured":"Julander, J. G. et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res. 137, 14\u201322 (2017).","journal-title":"Antiviral Res."},{"key":"BFja2017115_CR99","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","volume":"7","author":"MK Lo","year":"2017","unstructured":"Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 7, 43395 (2017).","journal-title":"Sci. Rep."},{"key":"BFja2017115_CR100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-5793(76)80996-9","volume":"72","author":"A Endo","year":"1976","unstructured":"Endo, A., Kuroda, M. & Tanzawa, K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme a reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 72, 323\u2013326 (1976).","journal-title":"FEBS Lett."},{"key":"BFja2017115_CR101","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000321892","volume":"54","author":"M Mart\u00ednez-Gutierrez","year":"2011","unstructured":"Mart\u00ednez-Gutierrez, M., Castellanos, J. E. & Gallego-G\u00f3mez, J. C. Statins reduce dengue virus production via decreased virion assembly. Intervirology 54, 202\u2013216 (2011).","journal-title":"Intervirology"},{"key":"BFja2017115_CR102","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.21232","volume":"44","author":"M Ikeda","year":"2006","unstructured":"Ikeda, M. et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44, 117\u2013125 (2006).","journal-title":"Hepatology"},{"key":"BFja2017115_CR103","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3892\/mmr.2014.2076","volume":"9","author":"J Peng","year":"2014","unstructured":"Peng, J. et al. Protective effect of fluvastatin on influenza virus infection. Mol. Med. Rep. 9, 2221\u20132226 (2014).","journal-title":"Mol. Med. Rep."},{"key":"BFja2017115_CR104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.78.1.1-8.2004","volume":"78","author":"J Gigu\u00e8re","year":"2004","unstructured":"Gigu\u00e8re, J. & Tremblay, M. J. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell statin compounds reduce human immunodeficiency virus type 1 replica. J. Virol. 78, 1\u20135 (2004).","journal-title":"J. Virol."},{"key":"BFja2017115_CR105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.antiviral.2010.02.325","volume":"86","author":"T Bader","year":"2010","unstructured":"Bader, T. & Korba, B. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res. 86, 241\u2013245 (2010).","journal-title":"Antiviral Res."},{"key":"BFja2017115_CR106","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jecm.2013.08.001","volume":"5","author":"H Sadanari","year":"2013","unstructured":"Sadanari, H. et al. Inhibitory effects of statins on expression of immediate\u2013early 1 protein of human cytomegalovirus in virus-infected cells. J. Exp. Clin. Med. 5, 187\u2013193 (2013).","journal-title":"J. Exp. Clin. Med."},{"key":"BFja2017115_CR107","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7164\/antibiotics.25.109","volume":"22","author":"D Kluepfel","year":"1972","unstructured":"Kluepfel, D. et al. Myoriocin, a new antifungal antibiotic from Myriococcum arbomyces. J. Antibiot. (Tokyo) 22, 109\u2013115 (1972).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2017115_CR108","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nchembio742","volume":"1","author":"H Sakamoto","year":"2005","unstructured":"Sakamoto, H. et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat. Chem. Biol. 1, 333\u2013337 (2005).","journal-title":"Nat. Chem. Biol."},{"key":"BFja2017115_CR109","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jmv.21970","volume":"83","author":"K Tatematsu","year":"2011","unstructured":"Tatematsu, K., Tanaka, Y., Sugiyama, M., Sudoh, M. & Mizokami, M. Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication. J. Med. Virol. 83, 587\u2013593 (2011).","journal-title":"J. Med. Virol."},{"key":"BFja2017115_CR110","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1073\/pnas.1219909110","volume":"110","author":"FG Tafesse","year":"2013","unstructured":"Tafesse, F. G. et al. Intact sphingomyelin biosynthetic pathway is essential for intracellular transport of influenza virus glycoproteins. Proc. Natl Acad. Sci. USA 110, 6406\u20136411 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFja2017115_CR111","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.1128\/JVI.00980-12","volume":"86","author":"M Bienkowska-Haba","year":"2012","unstructured":"Bienkowska-Haba, M., Williams, C., Kim, S. M., Garcea, R. L. & Sapp, M. Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2\/DNA complex following virus entry. J. Virol. 86, 9875\u20139887 (2012).","journal-title":"J. Virol."},{"key":"BFja2017115_CR112","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.1073\/pnas.89.17.8351","volume":"89","author":"A Karpas","year":"1992","unstructured":"Karpas, A., Lowdell, M., Jacobson, S. K. & Hill, F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc. Natl Acad. Sci. USA 89, 8351\u20138355 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFja2017115_CR113","doi-asserted-by":"crossref","first-page":"e1002331","DOI":"10.1371\/journal.ppat.1002331","volume":"7","author":"S Pfefferle","year":"2011","unstructured":"Pfefferle, S. et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7, e1002331 (2011).","journal-title":"PLoS Pathog."},{"key":"BFja2017115_CR114","first-page":"1","volume":"7","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways. PLoS ONE 7, 1\u20138 (2012).","journal-title":"PLoS ONE"},{"key":"BFja2017115_CR115","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1099\/vir.0.037309-0","volume":"93","author":"LR Keyes","year":"2012","unstructured":"Keyes, L. R., Bego, M. G., Soland, M. & St. Jeor, S. Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation. J. Gen. Virol. 93, 722\u2013732 (2012).","journal-title":"J. Gen. Virol."},{"key":"BFja2017115_CR116","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","volume":"38","author":"K Watashi","year":"2003","unstructured":"Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282\u20131288 (2003).","journal-title":"Hepatology"},{"key":"BFja2017115_CR117","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda, S. & Koyasu, S. Mechanisms of action of cyclosporine. Immunopharmacology 47, 119\u2013125 (2000).","journal-title":"Immunopharmacology"},{"key":"BFja2017115_CR118","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1016\/j.bmcl.2013.05.101","volume":"23","author":"M Peel","year":"2013","unstructured":"Peel, M. & Scribner, A. Cyclophilin inhibitors as antiviral agents. Bioorganic Med. Chem. Lett. 23, 4485\u20134492 (2013).","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"BFja2017115_CR119","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00016-14","volume":"58","author":"U Chatterji","year":"2014","unstructured":"Chatterji, U. et al. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis c virus activity without detectable cross-resistance. Antimicrob. Agents Chemother. 58, 3327\u20133334 (2014).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ja2017115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ja2017115","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ja.2017.115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/ja2017115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:25:18Z","timestamp":1744151118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja2017115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFja2017115"],"URL":"https:\/\/doi.org\/10.1038\/ja.2017.115","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]},"assertion":[{"value":"12 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}